Intervention

Fulvestrant

ClinicalTrials.gov intervention label

Clinical trials299

Recruiting50

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

Rash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15

A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.NCT07666555 · 2026-06-06

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerNCT07604571 · 2026-05-28

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerNCT07558733 · 2026-04-22

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerNCT07405801 · 2026-04-07

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerNCT07368998 · 2026-02-18

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsNCT07287917 · 2026-01-26

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerNCT07347600 · 2026-01-21

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359 · 2025-12-29

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyNCT07330544 · 2025-11-24

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerNCT07180160 · 2025-09-25

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyNCT07117630 · 2025-09-25

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsNCT06998407 · 2025-08-20

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01

A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNCT07029399 · 2025-03-25

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNCT06856200 · 2025-02-28

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932 · 2025-02-04

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193 · 2024-12-16

Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorNCT05933395 · 2024-09-23

Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerNCT06409390 · 2024-08-14

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerNCT06515470 · 2024-07-03

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01

Study of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerNCT05601440 · 2023-06-13

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerNCT05735080 · 2023-03-28

VS-6766+Abema+Fulv in Met HR+/HER- BCNCT05608252 · 2023-02-23

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerNCT05683418 · 2023-02-15

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCNCT05720260 · 2023-01-17

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorNCT05536128 · 2022-12-31

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerNCT06954961 · 2022-09-15

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerNCT05467891 · 2022-09-13

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerNCT05524584 · 2022-08-31

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705 · 2022-05-11

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorNCT05181033 · 2021-12-27

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08

Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · 2020-11-16

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerNCT04263298 · 2018-05-01

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreNCT02476786 · 2017-01-17

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.NCT07679269 · 2026-12-15

NOT_YET_RECRUITING

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNCT07748208 · 2026-10-30

NOT_YET_RECRUITING

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.NCT07619066 · 2026-10-04

NOT_YET_RECRUITING

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNCT07716046 · 2026-10-01

NOT_YET_RECRUITING

A Phase 1/2a Study of K-1728 in Advanced Solid TumorsNCT07861932 · 2026-10-01

NOT_YET_RECRUITING

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNCT07811232 · 2026-09-01

NOT_YET_RECRUITING

Trastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast CancerNCT07857226 · 2026-09-01

NOT_YET_RECRUITING

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07570966 · 2026-06-30

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerNCT07408089 · 2026-02-25

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNCT07235618 · 2026-01-05

NOT_YET_RECRUITING

Common conditions

Leading sponsors

AstraZeneca27 Novartis Pharmaceuticals22 Eli Lilly and Company13 Hoffmann-La Roche12 Fudan University11 Pfizer10 National Cancer Institute (NCI)8 Dana-Farber Cancer Institute6 Genentech, Inc.5 Memorial Sloan Kettering Cancer Center5 Spanish Breast Cancer Research Group5 MedSIR4 Washington University School of Medicine4 BeOne Medicines3 Consorzio Oncotech3

Trial status mix

COMPLETED107

ACTIVE_NOT_RECRUITING54

RECRUITING50

TERMINATED43

UNKNOWN28

WITHDRAWN9

NOT_YET_RECRUITING8

Phase mix

PHASE2167

PHASE190

PHASE353

PHASE46

EARLY_PHASE12

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.